drugset / Trial / NCT00962104

Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder

NCT00962104

Phase 3 Completed 391 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).

Timeline

Start
2009-08
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 80 mg Oral
Subject Atomoxetine Other / unclassified 120 mg Oral